Related Experiment Video
Updated: Sep 16, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Exploring the potential value of SRC in pan cancer based on bioinformatics methods
Liyin Huang1,2, Yanwen Lu3, Lei Yi3
1Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China.
Background:
Tyrosine-Protein Kinase Src (SRC), a non-receptor tyrosine kinase encoded by the Src gene, plays a crucial role in cell growth, division, migration, and survival signaling pathways. Dysregulation of SRC expression and activity is associated with advanced stages of several human cancers and poor prognosis. However, the prognostic value of SRC across multiple cancers and its involvement in immune response remain unclear. Therefore, this study aimed to investigate the relationship between SRC expression levels and cancer patient prognosis, as well as its potential impact on the immune microenvironment.
Methods:
In this study, we utilized the Sangerbox database to investigate the differential expression of SRC in various types of cancer tumors and adjacent normal tissues. Survival outcomes of SRC expression levels in pan cancer were analyzed by Cox risk ratio and Kaplan Meier analysis. We further explored the relationship between SRC expression and immune regulatory genes, tumor mutation load, microsatellite instability, and the immune microenvironment of pan cancer using the Sangerbox database.
Results:
Compared to normal tissues, SRC expression is upregulated in various tumor tissues. SRC is significantly correlated with OS and in tumors such as LIHC and PRAD. Furthermore, SRC expression is significantly associated with mutation burden and microsatellite instability in tumors such as LUAD and COAD. In addition, SRC expression is related to the abundance of infiltrating immune cells in tumors such as LIHC and PRAD. These findings suggest that SRC may serve as a potential prognostic biomarker and therapeutic target for various cancers, and may be associated with the immune microenvironment of tumors.
Conclusion:
Our results suggest that SRC may play a role in regulating immune infiltration and impacting the prognosis of cancer patients, highlighting its potential as a therapeutic target and biomarker for various cancers.
Insights
Tyrosine-Protein Kinase Src (SRC) is upregulated in many cancers and linked to poor prognosis. This study reveals SRC’s association with immune cell infiltration and tumor characteristics, suggesting its potential as a prognostic biomarker and therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Tyrosine-Protein Kinase Src (SRC) is vital for cell signaling pathways.
- SRC dysregulation correlates with advanced cancers and poor prognosis.
- The prognostic value and immune role of SRC across diverse cancers are not fully understood.
Purpose of the Study:
- To investigate SRC expression in various cancers.
- To determine the prognostic significance of SRC in pan-cancer analysis.
- To explore SRC's relationship with the tumor immune microenvironment.
Main Methods:
- Utilized the Sangerbox database for differential SRC expression analysis.
- Performed Cox risk ratio and Kaplan-Meier analyses for survival outcomes.
- Assessed SRC's association with immune genes, mutation load, and microsatellite instability.
Main Results:
- SRC expression is upregulated in multiple tumor types compared to normal tissues.
- SRC levels correlate with overall survival (OS) in specific cancers (e.g., LIHC, PRAD).
- SRC is associated with tumor mutation burden, microsatellite instability, and immune cell infiltration in various cancers.
Conclusions:
- SRC may serve as a prognostic biomarker and therapeutic target in oncology.
- SRC expression is linked to immune infiltration and influences cancer patient prognosis.
- SRC warrants further investigation for its role in cancer development and immune response.
